Kodiak Sciences Says Tarcocimab Tedromer Shows 'Superiority' in Diabetic Retinopathy Phase 3 Trial

MT Newswires Live03-26 19:08

Kodiak Sciences (KOD) said Thursday that topline results from a phase 3 trial of tarcocimab tedromer demonstrated superiority over sham in patients with diabetic retinopathy and met its primary endpoint with high statistical significance.

The company said 62.5% of patients treated with tarcocimab achieved at least a two-step improvement in diabetic retinopathy severity score at week 48, compared with 3.3% in the sham group.

The investigational therapy also met key secondary endpoints, including an 85% reduction in the risk of developing sight-threatening complications compared with sham, and a higher proportion of patients achieving at least a three-step improvement in severity score, Kodiak Sciences said.

The company said the treatment was administered via intravitreal injection with all patients transitioned to a six-month dosing interval following a loading phase.

Kodiak Sciences added that tarcocimab demonstrated favorable safety was well tolerated with a 2.3% cataract adverse event rate.

Based on the results, Kodiak Sciences said tarcocimab now has a multi-indication biologics license application-ready profile and the company plans to accelerate its submission timeline.

Shares of Kodiak Sciences were up over 34% in premarket trading Thursday.

Price: 30.55, Change: +7.80, Percent Change: +34.29

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622190851?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 19:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622190851","market":"nz","top_or_hot":-1,"title":"Kodiak Sciences Says Tarcocimab Tedromer Shows 'Superiority' in Diabetic Retinopathy Phase 3 Trial","media":"MT Newswires Live","content":"<html><body><p> Kodiak Sciences (KOD) said Thursday that topline results from a phase 3 trial of tarcocimab tedromer demonstrated superiority over sham in patients with diabetic retinopathy and met its primary endpoint with high statistical significance.</p><p>The company said 62.5% of patients treated with tarcocimab achieved at least a two-step improvement in diabetic retinopathy severity score at week 48, compared with 3.3% in the sham group.</p><p>The investigational therapy also met key secondary endpoints, including an 85% reduction in the risk of developing sight-threatening complications compared with sham, and a higher proportion of patients achieving at least a three-step improvement in severity score, Kodiak Sciences said.</p><p>The company said the treatment was administered via intravitreal injection with all patients transitioned to a six-month dosing interval following a loading phase.</p><p>Kodiak Sciences added that tarcocimab demonstrated favorable safety was well tolerated with a 2.3% cataract adverse event rate.</p><p>Based on the results, Kodiak Sciences said tarcocimab now has a multi-indication biologics license application-ready profile and the company plans to accelerate its submission timeline.</p><p>Shares of Kodiak Sciences were up over 34% in premarket trading Thursday.</p><p>Price: 30.55, Change: +7.80, Percent Change: +34.29</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kodiak Sciences Says Tarcocimab Tedromer Shows 'Superiority' in Diabetic Retinopathy Phase 3 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKodiak Sciences Says Tarcocimab Tedromer Shows 'Superiority' in Diabetic Retinopathy Phase 3 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-26 19:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Kodiak Sciences (KOD) said Thursday that topline results from a phase 3 trial of tarcocimab tedromer demonstrated superiority over sham in patients with diabetic retinopathy and met its primary endpoint with high statistical significance.</p><p>The company said 62.5% of patients treated with tarcocimab achieved at least a two-step improvement in diabetic retinopathy severity score at week 48, compared with 3.3% in the sham group.</p><p>The investigational therapy also met key secondary endpoints, including an 85% reduction in the risk of developing sight-threatening complications compared with sham, and a higher proportion of patients achieving at least a three-step improvement in severity score, Kodiak Sciences said.</p><p>The company said the treatment was administered via intravitreal injection with all patients transitioned to a six-month dosing interval following a loading phase.</p><p>Kodiak Sciences added that tarcocimab demonstrated favorable safety was well tolerated with a 2.3% cataract adverse event rate.</p><p>Based on the results, Kodiak Sciences said tarcocimab now has a multi-indication biologics license application-ready profile and the company plans to accelerate its submission timeline.</p><p>Shares of Kodiak Sciences were up over 34% in premarket trading Thursday.</p><p>Price: 30.55, Change: +7.80, Percent Change: +34.29</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2622190851","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622190851","pubTimestamp":1774523339,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Kodiak Sciences  said Thursday that topline results from a phase 3 trial of tarcocimab tedromer demonstrated superiority over sham in patients with diabetic retinopathy and met its primary endpoint with high statistical significance.The company said 62.5% of patients treated with tarcocimab achieved at least a two-step improvement in diabetic retinopathy severity score at week 48, compared with 3.3% in the sham group.The investigational therapy also met key secondary endpoints, including an 85% reduction in the risk of developing sight-threatening complications compared with sham, and a higher proportion of patients achieving at least a three-step improvement in severity score, Kodiak Sciences said.The company said the treatment was administered via intravitreal injection with all patients transitioned to a six-month dosing interval following a loading phase.Kodiak Sciences added that tarcocimab demonstrated favorable safety was well tolerated with a 2.3% cataract adverse event rate.Ba","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KOD":"Kodiak Sciences Inc.","BK4505":"高瓴资本持仓"},"translate_title":"Kodiak Sciences表示Tarcocimab Tedromer在糖尿病视网膜病变3期试验中显示出“优越性”","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KOD":1},"content_text":"Kodiak Sciences (KOD) said Thursday that topline results from a phase 3 trial of tarcocimab tedromer demonstrated superiority over sham in patients with diabetic retinopathy and met its primary endpoint with high statistical significance.The company said 62.5% of patients treated with tarcocimab achieved at least a two-step improvement in diabetic retinopathy severity score at week 48, compared with 3.3% in the sham group.The investigational therapy also met key secondary endpoints, including an 85% reduction in the risk of developing sight-threatening complications compared with sham, and a higher proportion of patients achieving at least a three-step improvement in severity score, Kodiak Sciences said.The company said the treatment was administered via intravitreal injection with all patients transitioned to a six-month dosing interval following a loading phase.Kodiak Sciences added that tarcocimab demonstrated favorable safety was well tolerated with a 2.3% cataract adverse event rate.Based on the results, Kodiak Sciences said tarcocimab now has a multi-indication biologics license application-ready profile and the company plans to accelerate its submission timeline.Shares of Kodiak Sciences were up over 34% in premarket trading Thursday.Price: 30.55, Change: +7.80, Percent Change: +34.29","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622190851","isCrawlerRequest":true}